Today, directly-opposed results from RCTs about the duration of adjuvant trastuzumab for breast cancer were published in the Lancet.
The PERSEPHONE study concluded that 6-month adjuvant trastuzumab was non-inferior to 12-month treatment in patients with HER2-positive early breast cancer with less cardiotoxicity and fewer severe adverse events with median follow-up duration of 5.4 years.
In contrast, the PHARE study concluded that adjuvant trastuzumab standard duration should remain 12 months in these patients with the median follow-up duration of 7.5 years.
It’s worthy to read the editorial comment for these two articles.
We can compare the true long-term effect (survival, cardiotoxicity, and real cardiac event) of 6 month vs. 12 month trastuzumab therapy in the patients with HER-2 positive early breast cancer in the real world.